Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline Read more about Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate Read more about Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients Read more about Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference Read more about Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R)) Read more about Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))
Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference Read more about Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference
Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative Read more about Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study Read more about Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
Amgen Highlights Data to Be Presented at ASCO Read more about Amgen Highlights Data to Be Presented at ASCO
Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference Read more about Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference
